A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study)

Lung Cancer, 03/15/2012

In vulnerable elderly patients with non small–cell lung cancer (NSCLC) not selected for EGFR expression, both strategies were feasible but had modest efficacy.

Print Article Summary